The interstitial deletion that most commonly results in the TMPRSS2/ERG fusion deletes one copy of the ETS gene ETS2. The loss of ETS2 from this deletion, is associated with poor patient outcomes and promotes prostate cancer progression in a mouse model [18]. This evidence concerns the gene ERG and prostate cancer.